louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT04497467: Changes in Out-patient Visits in Taiwan During the Time of Global COVID-19 Pandemic
Official title: An Analysis of Changes in Out-patient Visits in Taiwan During the Time of Global COVID-19 Pandemic
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Patient Preference
Lead sponsor: National Taiwan University Hospital
Sponsor class: OTHER
First posted: 2020-08-04
Enrollment: 1200000
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: patients visited the out-patient clinic using the health insurance cards.

Brief summary: The COVID-19 pandemic becomes a global challenge. This study aims to analyze the possible changes in out-patient visits during the time of COVID-19 pandemic between January and June, 2020, compared with the same period in 2019, and the impact of the related healthy policies.

Detailed description: Using the statistical data of the Health Insurance Bureau, this study aims to analyze the possible changes in out-patient visits during the time of COVID-19 pandemic between January and June, 2020, compared with the same period in 2019, and the impact of the related healthy policies.

Eligibility criteria: Inclusion Criteria:

* patients visited the out-patient clinic using the health insurance cards.

Exclusion Criteria:

* patients visited the out-patient clinic without using the health insurance cards.

Primary outcomes:
measure: the number of the out-patient visits
timeFrame: 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Taipei
country: Taiwan
facility: National Taiwan University Hospital
Study officials:
affiliation: National Taiwan University Hospital
name: Wan-Ching Lien, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05476367: Patients With Asymptomatic Hyperuricemia Have Stronger Local Inflammatory Response and Worse Outcome After Total Knee Arthroplasty
Official title: Patients With Asymptomatic Hyperuricemia Have Stronger Local Inflammatory Response and Worse Outcome After Total Knee Arthroplasty
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Arthritis Knee
Lead sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University
Sponsor class: OTHER
First posted: 2022-07-27
Enrollment: 614
Sex: ALL
Minimum age (years): 18
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: All patients received primary TKA(totla knee arthroplasty) in our hospital.

Brief summary: We identify all patients who had undergone primary total knee arthroplsty(TKA) from April 1, 2015, to March 30, 2016. Patients are grouped by uric acid level. The knee society score(KSS score) and the hospital for special surgery knee score (HSS score) before the surgery and 6 years after the surgery will be collected. Also the clinical data will be collected.


Eligibility criteria: Inclusion Criteria:

* patients who had undergone primary TKA from April 1, 2015, to March 30, 2016

Exclusion Criteria:

* (1) infection, (2) rheumatoid arthritis, (3) ankylosing spondylitis, (4) revision surgery, (5) patients with unicondylar knee replacement, (6) patients who have been diagnosed with gout or previous gouty symptoms, and (7) patients combined with preoperative redness or swelling.

Primary outcomes:
measure: CRP
timeFrame: within 7 days after surgery
measure: temperature
timeFrame: within 7 days after surgery
measure: HSS score
timeFrame: 6 years after surgery
measure: KSS scores
timeFrame: 6 years after surgery
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT06622967: KNUCH CadAI-B-1(KCB-1)
Official title: Multinational Clinical Trial of Real-time Artificial Intelligence System (CadAI-B) for Breast Ultrasound: Prospective Clinical Validation Study
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: NA
Conditions: Breast Neoplasm
Female
Keywords: breast neoplasm
ultrasound
Lead sponsor: Kyungpook National University Chilgok Hospital
Sponsor class: OTHER
Collaborators: name: Kyungpook National University Chilgok Hospital
name: BeamWorks Inc.
First posted: 2024-10-02
Enrollment: 100
Sex: FEMALE
Minimum age (years): 20
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: The CadAI-B (Computer Aided Design Artificial Intelligence-Breast) system is a real-time AI diagnostic tool for breast ultrasound. It integrates with ultrasound devices to detect suspicious lesions, providing size, BI-RADS, and malignancy probability. After installation and user training, the system displays real-time breast conditions and automatically analyzes lesions when a freeze frame is set, showing results in seconds. This study will assess CadAI-B\&#39;s accuracy and reliability by comparing its findings with biopsy results.


Eligibility criteria: Inclusion Criteria:

* Women aged 20 years or older
* Individuals scheduled to undergo breast ultrasound for diagnostic evaluation
* Patients whose Ground Truth can be determined through biopsy, surgery, or follow-up

Exclusion Criteria:

* Images containing artifacts that may affect the interpretation
* Presence of breast implants
* Significant breast trauma or mastitis at the time of the breast ultrasound that could cause distortion in image interpretation
* History of surgery or chemotherapy

Primary outcomes:
measure: Lesion and Per-patient Diagnostic Performance
timeFrame: At the end of the trial, up to 6 months
Secondary outcomes:
measure: Lesion and Per-patient Detection Performance
timeFrame: At the end of the trial, up to 6 months
Other outcomes:
measure: BeamWorks Usability Evaluation Scale (Score of BeamWorks System Usability Scale (SUS))
timeFrame: At the end of the trial, up to 6 months
Locations:
city: Daegu
country: Korea, Republic of
facility: Kyungpook National University Chilgok Hospital
Study officials:
affiliation: Kyungpook National University Chilgok Hospital
name: Jeeyeon Lee, MD, PhD
role: STUDY_CHAIR
References:
Clinical trial NCT03447067: Computer Guided Versus Conventional Surgical Removal of Deeply Impacted Mandibular Third Molar With Preservation of External Oblique Ridge
Official title: Computer Guided Versus Conventional Surgical Removal of Deeply Impacted Mandibular Third Molar With Preservation of External Oblique Ridge
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Impacted Third Molar Tooth
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2018-02-27
Enrollment: 18
Sex: ALL
Minimum age (years): 16
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: in patent have deeply impacted lower third molar ,dose computer guided enhance surgical outcome versus conventional surgical remove of wisdom teeth

Detailed description: P- Patient with deeply impacted mandibular molar I- Computer guided surgical cutting stent C- Conventional extraction O- Clinical outcome sound radiographic outcomes primary outcome

- pain : each patient well be asked to rate current and worst pain intensity on visual analogue scale (VAS ) of 0-10 with Zero being no pain and Ten corresponds to the worst pain.

Secondary outcome

* evaluation of maximum inter incisal opening: assessment of MMO will be performed by measuring the distance in mm between the incisal edges of the upper and lower central incisor by using tape graduated method.
* evaluation of edema throw use nylon thread.

Eligibility criteria: Inclusion Criteria:

* patient with deeply impacted mandibular third molar
* patients should be free from any systematic disease that affect normal healing

Exclusion Criteria:

* -Patient with soft tissue impaction and impaction class A position 1
* Medical problem that may interfere with the procedures such as bleeding disorder \& pregnant.
* Uncooperative patient.

Primary outcomes:
measure: Pain
timeFrame: immediate post operative ,at three day pain change till fourteen day day .
Secondary outcomes:
measure: evaluation of maximum inter incisal opening
timeFrame: immediate post operative ,at three day inter incisal change till fourteen day .
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT04332367: Carboplatin, Taxane And Ramucirumab for Patients With NSCLC After Pemetrexed or Pembrolizumab Maintenance
Official title: Phase II, Single-Arm Study Of Carboplatin, Weekly Taxane, And Ramucirumab In Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC) After Progressive Disease On Maintenance Pemetrexed And/Or Pembrolizumab
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE2
Conditions: Non-small Cell Lung Cancer
Lead sponsor: Abramson Cancer Center at Penn Medicine
Sponsor class: OTHER
First posted: 2020-04-02
Enrollment: 59
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine if the combination of the three anti-cancer drugs carboplatin, paclitaxel, and ramucirumab is helpful in shrinking tumors or delaying tumor growth in participants with non-small cell lung cancer. This study will also assess whether it is safe to combine these drugs.


Eligibility criteria: Inclusion Criteria:

* Advanced non-squamous NSCLC (Stage IV or recurrent after initial curative intent therapy) in adults age 18 or older
* Prior exposure to 4-6 cycles of Pem/Carbo/Pembro and PD after at least 18 weeks of maintenance Pemetrexed, Pembrolizumab or the combination of the two.
* PS 0-1

Exclusion Criteria:

* Presence of a driver mutation that is susceptible to targeted therapy
* Other active invasive malignancy requiring ongoing therapy
* Grade 2 or higher sensory neuropathy
* Evidence of untreated brain metastases
* History of bleeding diatheses or recent, antecedent hemoptysis (\> 1/2 teaspoon in prior 2 months)

Primary outcomes:
measure: To estimate overall response rate
timeFrame: 3 years
Secondary outcomes:
measure: Progression-free survival
timeFrame: From first dose of study drug until progressive disease, death or last assessment contact, whichever comes first, an average of 1-2 years
measure: Overall Survival
timeFrame: from the first dose of study drug until death, last observation or contact, an average of 1-2 years
measure: Safety Evaluations: number of Grade ≥ 3 as determined by CTCAE v 5.0
timeFrame: Initiation through 30 days following the last administration of study treatment.
Other outcomes:
Locations:
city: Philadelphia
country: United States
facility: Abramson Cancer Center of the University of Pennsylvania
state: Pennsylvania
Study officials:
affiliation: Abramson Cancer Center at Penn Medicine
name: Melina Marmarelis, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00914667: The Effect Of Fesoterodine On Pharmacokinetics And Pharmacodynamics Of Warfarin In Healthy Subjects
Official title: An Open-Label, Randomized, Two-Way Crossover Study To Evaluate The Steady-State Effect Of Fesoterodine On The Pharmacokinetics And Pharmacodynamics Of A Single Supratherapeutic Dose Of Warfarin In Healthy Subjects.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Urinary Bladder, Overactive
Keywords: Overactive Bladder Urgency Frequency
Lead sponsor: Pfizer
Sponsor class: INDUSTRY
First posted: 2009-06-05
Enrollment: 14
Sex: ALL
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: This is an open-label, randomized, two-way crossover study to evaluate the steady-state effect of fesoterodine (8 mg QD) on the pharmacodynamics and pharmacokinetics of a single supratherapeutic dose of warfarin (25 mg) in healthy subjects.


Eligibility criteria: Inclusion Criteria:

* Healthy male and/or female subjects between the ages of 18 and 55 years

Exclusion Criteria:

* Not healthy subjects--subjects with acute or chronic medical or psychiatric conditions or laboratory abnormality

Primary outcomes:
measure: Cmax and AUCinf for both S- and R-warfarin
timeFrame: 8 days per period
measure: AUC_INR and INRmax
timeFrame: 8 days per period
Secondary outcomes:
measure: AUClast, Tmax and t½ for both S- and R-warfarin
timeFrame: 8 days per period
measure: AUC_PT and PTmax
timeFrame: 8 days per period
measure: Safety will be assessed by subjective symptoms/objective findings including physical examinations, clinical safety laboratory assessments, 12-lead ECGs, vital sign measurements and adverse event monitoring.
timeFrame: 8 days per period
Other outcomes:
Locations:
city: New Haven
country: United States
facility: Pfizer Investigational Site
state: Connecticut
Study officials:
affiliation: Pfizer
name: Pfizer CT.gov Call Center
role: STUDY_DIRECTOR
References:
Clinical trial NCT06195267: Protective Effect of Sivelestat Against Negative Pulmonary Function and Organ Dysfunction After Cardiovascular Surgery (PANDA VI)
Official title: Protective Effect of Sivelestat Against Negative Pulmonary Function and Organ Dysfunction After Cardiovascular Surgery (PANDA VI)
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Aortic Dissection
Systemic Inflammatory Response Syndrome
Cardiovascular Diseases (CVD)
Keywords: Systemic Inflammatory Response Syndrome
Lead sponsor: Nanjing Medical University
Sponsor class: OTHER
Collaborators: name: The First Affiliated Hospital with Nanjing Medical University
name: Beijing Anzhen Hospital
First posted: 2024-01-08
Enrollment: 500
Sex: ALL
Minimum age (years): 18
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Systemic inflammatory response syndrome (SIRS) and multiple organ dysfunction syndrome (MODS) are the major causes of death in patients with cardiovascular diseases. Therefore, the prevention of SIRS and MODS is of great clinical value, and immunomodulatory therapy with sivelestat may be beneficial. This study was designed to test the hypothesis that the administration of sivelestat during the acute phase of cardiovascular diseases will result in a reduced incidence of SIRS and MODS.


Eligibility criteria: Inclusion Criteria:

* The patients are conformed to 2010 ACC/AHA guidelines for the diagnosis and treatment of thoracic aortic disease (TAD) within two weeks of onset;
* Patients with type A acute aortic syndrome confirmed clinically and radiologically and planning to undergo emergency surgery were enrolled.
* The patients' age between 18 \~90 years old.
* Agree to participate in the study and sign the informed consent.

Exclusion Criteria:

* Patients allergic to sivelestat sodium;
* Lactating women and pregnant women;
* Patients with mental diseases, drug and alcohol dependence;
* Refuse to participate in this study and refuse to sign the informed consent.

Primary outcomes:
measure: The highest SOFA score of 7 days after surgery
timeFrame: 7 days after surgery
Secondary outcomes:
measure: all-cause mortality
timeFrame: 30 days after surgery
Other outcomes:
Locations:
city: Beijing
country: China
facility: Beijing Anzhen Hospital
city: Nanjing
country: China
facility: The First Affiliated Hospital of Nanjing Medical University and Jiang ye-fan
Study officials:
References:
Clinical trial NCT03158467: RCT of ACP for Transplant
Official title: A Pilot Randomized Control Trial of Advance Care Planning and Triggered Palliative Care for Cancer Patients Undergoing Stem Cell Transplantation (RCT of ACP for Transplant)
Study type: OBSERVATIONAL
Overall status: WITHDRAWN
Conditions: Cancer Patients Undergoing Stem Cell Transplantation (RCT of ACP for Transplant)
Lead sponsor: Abramson Cancer Center at Penn Medicine
Sponsor class: OTHER
First posted: 2017-05-18
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Cancer Patients Undergoing Stem Cell Transplantation

Brief summary: We aim to examine the effect of an online advance directive on decisional conflict and quality of life in patients undergoing stem cell transplant. We also aim to assess the effect of palliative care at the time of a sentinel event on quality of life.


Eligibility criteria: Inclusion Criteria:

The inclusion criteria for Phase I (primary objective) are as follows:

* Age ≥ 18 years
* Hematologic malignancy diagnosis including any subset of myeloma, lymphoma, leukemia, or myelodysplastic syndrome
* Currently scheduled for autologous or allogeneic transplant at the Hospital of the University of Pennsylvania

The inclusion criteria for Phase II (secondary objective) are as follows:

* Age ≥ 18 years
* Hematologic malignancy diagnosis including any subset of lymphoma, leukemia, or myelodysplastic syndrome
* Received an autologous or allogeneic stem cell transplant at the Hospital of the University of Pennsylvania and experienced a sentinel event of either 1) disease relapse,2) severe (Grade III or IV) graft-versus-host disease, or 3) unplanned hospital admission with length of stay greater than 72 hours.

Exclusion Criteria:

The exclusion criteria for Phase I include:

* Inability to read and write English
* Not serving as the primary decision maker for their health-related decisions
* Having a non-hematologic malignancy reason for undergoing transplantation (e.g. aplastic anemia)

The exclusion criteria for Phase II include:

* Not completing participation in Phase I of the study
* Myeloma diagnosis

Primary outcomes:
measure: Number of surveys completed
timeFrame: 2 years
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Abramson Cancer Center at Penn Medicine
name: Pallavi Kumar, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01430767: Measuring Adherence to Medication for Depression and Attention-deficit Hyperactivity Disorder
Official title: Measuring Adherence to Standard-of-Care Medication for Depression and ADHD in a College Student Population
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Major Depressive Disorder
Attention-deficit Hyperactivity Disorder (ADHD)
Keywords: adherence
Lead sponsor: Wake Forest University Health Sciences
Sponsor class: OTHER
First posted: 2011-09-08
Enrollment: 33
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Twenty male and female subjects, ten with depression and ten with ADHD, will be recruited. Subjects will be recruited from the Student Health Clinic at Wake Forest University, as we plan to assess adherence in a typical population of college students with depression or ADHD.

Brief summary: Poor adherence is a common reason for treatment failure in many fields of medicine, and likely affects common psychiatric treatments as well. Members of the present study team have used Medication Event Monitoring System (MEMS®) caps effectively to objectively monitor adherence in skin disease, and have shown that they provide a much more accurate measure of adherence behavior than self-reports, pill counts, or serum drug concentrations. The present study will use MEMS® caps to measure adherence in 10 patients with depression and 10 patients with attention-deficit hyperactivity disorder (ADHD) from a student clinic population. The aims will be to show the usefulness of MEMS® caps in measuring adherence to psychiatric treatment, and gather data on typical adherence rates for depression and ADHD patients on typical treatment regimens. The data obtained will be used to inform future studies that use an intervention to improve adherence behavior and ultimately disease outcomes.


Eligibility criteria: Inclusion Criteria:

* Any male or female, at least 18 years of age, using the Student Health Clinic, with a diagnosis of depression or ADHD.
* Written consent of participation must be given by the subject.

Exclusion Criteria:

* Subject is less than 18 years of age.
* Inability to complete all study-related visits.
* Introduction of any other prescription medication while participating in the study. (Patients who are on a stable dose of non-study-related prescription medications for at least 4 weeks prior to the study, and throughout the study period, are not excluded.)
* Female patients whose medications may be harmful during pregnancy must be on an acceptable form of birth control, otherwise they will not be eligible for participation.

Primary outcomes:
measure: Adherence to Standard-of-Care Medication for Depression or ADHD
timeFrame: 4 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Winston-Salem
country: United States
facility: Wake Forest University Health Sciences
state: North Carolina
Study officials:
affiliation: Wake Forest University Health Sciences
name: Guy K Palmes, MD
role: PRINCIPAL_INVESTIGATOR
References: